Reversion of CTL escape-variant immunodeficiency viruses in vivo - PubMed (original) (raw)
doi: 10.1038/nm998. Epub 2004 Feb 15.
Elizabeth J Dodds, Levi J Yant, Lara Vojnov, Richard Rudersdorf, Candice Cullen, David T Evans, Ronald C Desrosiers, Bianca R Mothé, John Sidney, Alessandro Sette, Kevin Kunstman, Steven Wolinsky, Michael Piatak, Jeffrey Lifson, Austin L Hughes, Nancy Wilson, David H O'Connor, David I Watkins
Affiliations
- PMID: 14966520
- DOI: 10.1038/nm998
Reversion of CTL escape-variant immunodeficiency viruses in vivo
Thomas C Friedrich et al. Nat Med. 2004 Mar.
Abstract
Engendering cytotoxic T-lymphocyte (CTL) responses is likely to be an important goal of HIV vaccines. However, CTLs select for viral variants that escape immune detection. Maintenance of such escape variants in human populations could pose an obstacle to HIV vaccine development. We first observed that escape mutations in a heterogeneous simian immunodeficiency virus (SIV) isolate were lost upon passage to new animals. We therefore infected macaques with a cloned SIV bearing escape mutations in three immunodominant CTL epitopes, and followed viral evolution after infection. Here we show that each mutant epitope sequence continued to evolve in vivo, often re-establishing the original, CTL-susceptible sequence. We conclude that escape from CTL responses may exact a cost to viral fitness. In the absence of selective pressure upon transmission to new hosts, these original escape mutations can be lost. This suggests that some HIV CTL epitopes will be maintained in human populations.
Comment in
- HIV escape: there and back again.
Altman JD, Feinberg MB. Altman JD, et al. Nat Med. 2004 Mar;10(3):229-30. doi: 10.1038/nm0304-229. Nat Med. 2004. PMID: 14991039 No abstract available.
Similar articles
- Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants.
Barouch DH, Powers J, Truitt DM, Kishko MG, Arthur JC, Peyerl FW, Kuroda MJ, Gorgone DA, Lifton MA, Lord CI, Hirsch VM, Montefiori DC, Carville A, Mansfield KG, Kunstman KJ, Wolinsky SM, Letvin NL. Barouch DH, et al. Nat Immunol. 2005 Mar;6(3):247-52. doi: 10.1038/ni1167. Epub 2005 Jan 30. Nat Immunol. 2005. PMID: 15685174 - Reversion in vivo after inoculation of a molecular proviral DNA clone of simian immunodeficiency virus with a cytotoxic-T-lymphocyte escape mutation.
Kobayashi M, Igarashi H, Takeda A, Kato M, Matano T. Kobayashi M, et al. J Virol. 2005 Sep;79(17):11529-32. doi: 10.1128/JVI.79.17.11529-11532.2005. J Virol. 2005. PMID: 16103206 Free PMC article. - Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency virus gag.
Chen ZW, Shen L, Miller MD, Ghim SH, Hughes AL, Letvin NL. Chen ZW, et al. J Immunol. 1992 Dec 15;149(12):4060-6. J Immunol. 1992. PMID: 1460291 - Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
Kent SJ, Fernandez CS, Dale CJ, Davenport MP. Kent SJ, et al. Trends Microbiol. 2005 Jun;13(6):243-6. doi: 10.1016/j.tim.2005.03.011. Trends Microbiol. 2005. PMID: 15936652 Review. - Understanding cytotoxic T-lymphocyte escape during simian immunodeficiency virus infection.
O'Connor D, Friedrich T, Hughes A, Allen TM, Watkins D. O'Connor D, et al. Immunol Rev. 2001 Oct;183:115-26. doi: 10.1034/j.1600-065x.2001.1830110.x. Immunol Rev. 2001. PMID: 11782252 Review.
Cited by
- A binary trait model reveals the fitness effects of HIV-1 escape from T cell responses.
Gao Y, Barton JP. Gao Y, et al. bioRxiv [Preprint]. 2024 Oct 6:2024.03.03.583183. doi: 10.1101/2024.03.03.583183. bioRxiv. 2024. PMID: 38464239 Free PMC article. Preprint. - Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies.
Rouzine IM, Rozhnova G. Rouzine IM, et al. Commun Med (Lond). 2023 Jun 19;3(1):86. doi: 10.1038/s43856-023-00320-x. Commun Med (Lond). 2023. PMID: 37336956 Free PMC article. Review. - No Difference in the Prevalence of HIV-1 gag Cytotoxic T-Lymphocyte-Associated Escape Mutations in Viral Sequences from Early and Late Parts of the HIV-1 Subtype C Pandemic in Botswana.
Mokaleng B, Choga WT, Bareng OT, Maruapula D, Ditshwanelo D, Kelentse N, Mokgethi P, Moraka NO, Motswaledi MS, Tawe L, Koofhethile CK, Moyo S, Zachariah M, Gaseitsiwe S. Mokaleng B, et al. Vaccines (Basel). 2023 May 19;11(5):1000. doi: 10.3390/vaccines11051000. Vaccines (Basel). 2023. PMID: 37243104 Free PMC article. - HLA-B∗46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype.
Li SS, Hickey A, Shangguan S, Ehrenberg PK, Geretz A, Butler L, Kundu G, Apps R, Creegan M, Clifford RJ, Pinyakorn S, Eller LA, Luechai P, Gilbert PB, Holtz TH, Chitwarakorn A, Sacdalan C, Kroon E, Phanuphak N, de Souza M, Ananworanich J, O'Connell RJ, Robb ML, Michael NL, Vasan S, Thomas R. Li SS, et al. Cell Host Microbe. 2022 Aug 10;30(8):1173-1185.e8. doi: 10.1016/j.chom.2022.06.005. Epub 2022 Jul 15. Cell Host Microbe. 2022. PMID: 35841889 Free PMC article. - Functional Profile of CD8+ T-Cells in Response to HLA-A*02:01-Restricted Mutated Epitopes Derived from the Gag Protein of Circulating HIV-1 Strains from Medellín, Colombia.
Sánchez-Martínez A, Acevedo-Sáenz L, Alzate-Ángel JC, Álvarez CM, Guzmán F, Roman T, Urcuqui-Inchima S, Cardona-Maya WD, Velilla PA. Sánchez-Martínez A, et al. Front Immunol. 2022 Mar 22;13:793982. doi: 10.3389/fimmu.2022.793982. eCollection 2022. Front Immunol. 2022. PMID: 35392101 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- N01-AI-95362/AI/NIAID NIH HHS/United States
- P51 RR001676-43/RR/NCRR NIH HHS/United States
- R01-AI-46366/AI/NIAID NIH HHS/United States
- R01-AI-49120/AI/NIAID NIH HHS/United States
- R01-AI-52056/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources